Hostname: page-component-745bb68f8f-grxwn Total loading time: 0 Render date: 2025-01-10T18:12:48.508Z Has data issue: false hasContentIssue false
  • English
  • Français

Safety of selective serotonin reuptake inhibitors in pregnancy

Published online by Cambridge University Press:  02 January 2018

Allison Donnelly  and
Carol Paton
Allison Donnelly
Affiliation:
Oxleas NHS Foundation Trust
Carol Paton
Affiliation:
Oxleas NHS Foundation Trust, Pinewood House, Pinewood Place, Dartford, Kent DA2 7WG, email: [email protected]
Rights & Permissions [Opens in a new window]

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Aims and Method

Selective serotonin reuptake inhibitors (SSRIs) are recommended by the National Institute for Clinical Excellence as first-line drugs for the treatment of depression, but there is emerging evidence that they might not be entirely safe in pregnancy. We reviewed the literature in this area.

Results

Some data indicate an association between first-trimester SSRI exposure, particularly with paroxetine, and an increased risk of some major congenital malformations. Stronger evidence supports an association with small reductions in gestational age and neonatal withdrawal symptoms.

Clinical Implications

Risks and benefits of using SSRIs during pregnancy should be discussed with the patient, and a joint decision made between prescriber and patient regarding treatment. Limited data suggest that other SSRIs are safer than paroxetine in pregnancy.

Type
Medicines information
Information
Psychiatric Bulletin , Volume 31 , Issue 5 , May 2007 , pp. 183 - 186
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution (CC-BY) license (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
Copyright © Royal College of Psychiatrists, 2007

References

Alwan, S., Reefhuis, J., Rasmussen, S., et al (2005) Maternaluse of selective serotonin reuptake inhibitors and risk for birth defect. Clinical and Molecular Teratology, 731, 291.Google Scholar
Chambers, C. D., Hernandez-Diaz, S., Van Marter, L. J., et al (2006) Selective serotonin reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. New England Journal of Medicine, 354, 579–588.Google Scholar
Cohen, L. S., Sichel, D. A., Robertson, L. M., et al (1995) Postpartum prophylaxis for women with bipolar disorder. American Journal of Psychiatry, 152, 1641–1644.Google Scholar
Cohen, L. S., Altshuler, L. L., Harlow, B. L., et al (2006) Relapse of major depression during pregnancy in women who maintain or discontinue antidepressant treatment. JAMA, 295, 499–507.Google Scholar
Diav-Citrin, O., Shechtman, S., Weinbaum, D., et al (2005) Paroxetine and fluoxetine in pregnancy: a multicenter, prospective, controlled study. Reproductive Toxicology, 20, 459.Google Scholar
Einerson, T. & Einerson, A. (2005) Newer antidepressants in pregnancy and rates of major malformations: a meta-analysis of prospective comparative studies. Pharmacoepidemiology & Drug Safety, 14, 823–827.Google Scholar
Glaxosmithkline (2006) Use of Paxil CR or Paxil During Pregnancy (medical information letter). http://www.gsk.com/media/paroxetine/mi_letter_paroxetine_pregnancy.pdf Google Scholar
Kallen, B. (2004) Neonate characteristics after maternal use of antidepressants in late pregnancy. Archives of Pediatric Adolescent Medicine, 158, 312–316.CrossRefGoogle ScholarPubMed
Levinson-Castiel, R., Merlob, P., Linder, N., et al (2006) Neonatal abstinence syndrome after in-utero exposure to selective serotonin reuptake inhibitors in term infants. Archives of Pediatric Adolescent Medicine, 160, 173–176.Google Scholar
Malm, H., Klaukka, T., Neuvonen, P. J. (2005) Risks associated with selective serotonin reuptake inhibitors in pregnancy. Obstetrics and Gynecology, 106, 1289–1296.Google Scholar
National Institute for Clinical Excellence (2004) Depression: Management of Depression in Primary and Secondary Care. NICE.Google Scholar
Nelson, K. & Holmes, L. B. (1989) Malformations due to presumed spontaneous mutations in newborn infants. New England Journal of Medicine, 320, 19–23.CrossRefGoogle ScholarPubMed
Sanz, E. J., De-Las-Cuevas, C., Kiuru, A., et al (2005) Selective serotonin reuptake inhibitors in pregnant women and neonatal withdrawal syndrome: a database analysis. Lancet, 365, 482–487.Google Scholar
Simon, G. E., Cunningham, M. L., Davis, R. L. (2002) Outcomes of prenatal antidepressant exposure. American Journal of Psychiatry, 159, 2055–2061.Google Scholar
Wen, S.W., Yand, Q., Garner, P., et al (2006) Selective serotonin reuptake inhibitors and adverse pregnancy outcomes. American Journal of Obstetrics and Gynecology, 194, 961–966.Google Scholar
Wogelius, P., Norgaard, M., Munk, E. M., et al (2005) Maternal use of selective serotonin reuptake inhibitors and risk of adverse pregnancy outcome. Pharmacoepidemiology and Drug Safety, 14, S72.Google Scholar
World Health Organization (2001) Fact Sheet: The World Health Report. Mental and Neurological Disorders. WHO.Google Scholar
Zeskind, P. S. & Stephens, L. E. (2005) Maternal selective serotonin reuptake inhibitor use during pregnancy and new born neurobehaviours. Paediatrics, 113, 368–375.Google Scholar
Submit a response

eLetters

No eLetters have been published for this article.